3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Alessio Lorusso of Roboze, Tobi Smith of All I Do Is Cook, and Pradeep Sharma of the University of Houston. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from 3D printing to food and cooking — recently making headlines in Houston innovation.

Alessio Lorusso, founder and CEO of Roboze

Alessio Lorusso joins the Houston Innovators Podcast to discuss why he chose Houston to set up U.S. operations for his large-scale 3D printing company, and how the city has the potential to become a hub for the industry. Photo via LinkedIn

The hit the pandemic has had on the global supply chain has been a huge hit to so many companies. However, one Italian company with its United States headquarters in Houston, has an alternative for customers — large scale, in-house production. Roboze, which recently completed a multimillion-dollar fundraise, has seen explosive growth due in large part to how COVID-19 has affected the global supply chain over this past two years.

"This was an incredible accelerator for us," says Alessio Lorusso, CEO and founder, on the Houston Innovators Podcast. He adds that, while Roboze has attracted large corporate customers, the business is seeing growth in the small to mid-sized company sector.

"The moment is now," Lorusso says. "The time to integrate printing capabilities and have the possibility to print parts in house is something that needs to be done now." Click here to read more and listen to the podcast.

Tobi Smith, founder of All I Do Is Cook

All I Do Is Cook is on a mission to grow accessibility to Nigerian dishes. Image via allidoiscook.com

Tobi Smith wanted to take his business to the next level — and he found the perfect opportunity to do so. After completing the gBETA accelerator program and winning the grand prize in the ClearCo ClearPitch competition, Smith and his business partner Bethany Oyefeso are transitioning their small business, All I Do Is Cook, into a startup with the ultimate goal of making Nigerian food accessible to everybody.

Smith and Oyefeso came one step closer to that goal when Phoencia, a Houston grocery story, started stocking the startup's condiments in 2021. In that same year, Smith and Oyefesso joined the gBETA accelerator program. Smith described this program as being instrumental in the advancement of their company from a small business to a start up, now at the beginning of their pre-seed funding phase.

“They taught us everything about what it meant to be a start up and connected us with mentors and other individuals working in the food and beverage space,” says Smith. Click here to read more.

Pradeep Sharma, engineering department chair at the University of Houston

Pradeep Sharma, M.D. Anderson Chair Professor and department chair at the University of Houston, was named to the National Academy of Engineering. Photo via uh.edu

The National Academy of Engineering elected its new members, and five local scientists are among the new 133-person cohort — as is Elon Musk, if you were wondering. The appointment is among the highest professional distinctions in an engineer's career.

Pradeep Sharma, M.D. Anderson Chair Professor and department chair, Department of Mechanical Engineering, University of Houston, was recognized for establishing the field of flexoelectricity, leading to the creation of novel materials and devices and insights in biophysical phenomena.

“Nature has provided us very few piezoelectric materials even though their applications in energy harvesting and in making sensors is very important. What we did was use theory to design materials that perform like piezoelectric ones, so that they can create electricity,” says Sharma in the release. Click here to read more.

All I Do Is Cook is on a mission to grow accessibility to Nigerian dishes. Image via allidoiscook.com

Unique Nigerian cuisine startup propelled by Houston accelerator heads into its next phase

cooking up growth

After completing the gBETA accelerator program and winning the grand prize in the ClearCo ClearPitch competition, Tobi Smith and Bethany Oyefeso are transitioning their small business, All I Do Is Cook, into a startup with the ultimate goal of making Nigerian food accessible to everybody.

Smith and Oyefeso came one step closer to that goal when Phoencia, a Houston grocery story, started stocking the startup's condiments in 2021. In that same year, Smith and Oyefesso joined the gBETA accelerator program. Smith described this program as being instrumental in the advancement of their company from a small business to a start up, now at the beginning of their pre-seed funding phase.

“They taught us everything about what it meant to be a start up and connected us with mentors and other individuals working in the food and beverage space,” says Smith.

It was during their time in the gBETA program that they learned about the ClearCo ClearPitch competition and would ultimately win the $20,000 grand prize.

“The last two years have been bonkers,” exclaims Smith, who started All I Do Is Cook as a blog in 2016, and grew it into a cooking business.

"When I arrived in Denton from Nigeria, I walked into Walmart expecting to find common Nigerian snacks but was surprised when I couldn’t find any so I started cooking my own food and sharing the recipes,” he says.

The pandemic and subsequent closing of restaurants sling-shotted them into overdrive where in just one year their number of total orders increased from 350 to over 2,000 which they then doubled in 2021 to over 4,000.

And if a focus on Nigerian food doesn’t already set them apart, their approach to production does. Smith shared that he and Oyefeso have focused heavily on the operations side of their business.

“We want everything to run as efficiently as possible with as little waste as possible,” says Smith. “We don’t carry an inventory. We only order as much produce as we need, and we only print as much packaging as we need. We know how much food we can produce in a week, and we use the timing and amount of orders as our indicator of when we might need to increase production.”

This focus on efficiency and mindfulness of the environment should keep them attractive to both investors and consumers alike.

“We are getting ready to kick off our pre-seed funding phase,” shares Smith, “and our goal is to get into the big supermarkets like Walmart, HEB, and Kroger.”

Tobi Smith and Bethany Oyefeso are taking their startup to the next level. Photos via allidoiscook.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings